3M to exit Neoplast, Neobun brands in Southeast Asia

July 1 (Reuters) - Industrial conglomerate 3M Co MMM.N said on Friday it will exit its Neoplast and Neobun brands in Thailand and some other Southeast Asian countries, and sell manufacturing assets at its Ladlumkaew plant, as part of its strategic portfolio management.

The brands — part of the company's Consumer Health and Safety Division (CHSD) — and the assets from its Thailand-based Ladlumkaew plant will be sold to Selic Corp PCL SELICm.BK , 3M said.

The St. Paul, Minnesota-based company did not disclose the terms of the deal, but said the sale will not have a material impact on its financial results.

"As part of ongoing strategic portfolio management, 3M has decided to exit these brands and prioritize other areas within its Consumer Health & Safety Division," 3M said.

Neoplast makes surgical tapes, dressings and first aid bandages, while Neobun makes menthol plasters for muscle pain.

The brands are sold primarily in Thailand and Southeast Asia and were a part of 3M's larger CHSD that includes sports and medical tapes, bandages and medicated products for the consumer and healthcare industry, according to the company.

3M also said its plan to sell the Ladlumkaew plant will impact about 250 employees in the country, and the affected employees are eligible for severance and outplacement assistance.

The U.S.-based company had acquired Neoplast in 2007.
Reporting by Ann Maria Shibu in Bengaluru; editing by Uttaresh.V

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.